Researchers assigned 13 National Psoriasis Foundation scholarship to study psoriasis

Researchers assigned 13 National Psoriasis Foundation scholarship to study psoriasis -

Nearly half a million dollars given to early career physicians studying psoriatic diseases

Twelve residents and medical students each received a year, 50,000 National psoriasis Foundation scholarship to study $ psoriasis. Awards are intended to increase the number of scientists who study and treat psoriatic diseases by promoting promising doctors to devote their careers to the study of psoriasis as medical researchers.

The program pairs an early career physician with psoriatic disease researcher established to oversee their work. Learn more about the scholarship program of the Psoriasis Foundation: www.psoriasis.org/fellowships.

The National Psoriasis Foundation Medical Dermatology Fellows for 2014 are:

• Dena Elkeeb, MD, from the University of Utah, will develop a group of pediatric study in the Utah psoriasis Initiative to assess the impact of systemic corticosteroids on physical characteristics psoriasis, its severity and the patient's overall health.

• Aleksandra Florek, MD, from the University of Colorado Denver, will study the epidemiology of psoriatic disease and health risks, or comorbidities, and investigate issues related to treatment of psoriasis, such as cost and efficiency

the National psoriasis Foundation medical Dermatology scholarships Amgen , supported by a grant Amgen, are :.

• Zelma Fuxench Chiesa, MD, from the University of Pennsylvania Perelman School Of Medicine, will determine the risk of major cardiovascular events in people with psoriasis and if treatment with the drug Humira (adalimumab) improves vascular inflammation. It will also study the effect of certain psoriasis treatments on the risk of skin cancer.

• Jessica Donigan, MD, MPH, of Massachusetts General Hospital / Harvard Medical School, will evaluate why psoriasis plaques appear to be more stigmatizing than the lesions of other dermatological diseases. efficiency

• Rivka Friedland, MD, Northwestern University, will examine the safety and systemic medications and phototherapy on psoriasis in children.

• Dario Kivelivetch, MD, of Baylor Research Institute, will assess cardiovascular risk in people with psoriasis using coronary artery calcium scores, which are special X-ray tests that can check for early heart disease to determine its severity.

• Davida Kornreich, MD, from Mt. Sinai Icahn School of Medicine, will analyze whether the topicals applied in different orders exchange efficiency. Kornreich also study the safety and efficacy of a moderate holistic treatment to severe plaque psoriasis.

• Marina Li, BS, student a third year medical student at Case Western Reserve University, will examine whether reducing inflammation of the skin also reduces blood clots and other cardiovascular disease signs.

• Forum Patel, MD, from the University of California, Davis, will identify if the glycans called complex sugars are biomarkers or biological signs psoriasis.

• Scott Santilli, MD, University Hospital Case Medical Center, will examine the effect of systemic, or whole-body, the therapy psoriasis and its potential for regulating the cardiovascular risk in people with psoriasis.

• Aimee Two, MD, from the University of California, San Diego, study the role of dendritic cells or pro-inflammatory cells in the immune system, in psoriasis and if hyaluronidase, an enzyme that can cause dendritic cells to move away from the skin, can be effective to stop inflammation.

• Shaowei Wu, MD, Ph.D., Brown University, use data from two ongoing Nurses Health Studies national to study the relationship between pregnancy, menstruation, menopause and hormone use after menopause the risk of psoriatic disease.

Furthermore, the recipient Dr. Mark G. Lebwohl Medical Dermatology Fellowship , named to recognize Dr. Mark Lebwohl, president emeritus of the National Psoriasis Foundation Medical Board and a major world psoriasis experts, is

• Emily Wicker, MD, of Rady Children's Hospital, University of California, San Diego, who will develop screening guidelines for comorbidities or risk associated health in children with psoriasis.